Joseph Shaughnessy, MD
Radiation Oncology · Cincinnati, OHNPI 1134361371
Payments from drug & device makers
What this record shows
Elekta, Inc. accounts for 65.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $732 and has fallen 78.4% since, to $158 in 2025.
Across 10 payments — averaging $123.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elekta, Inc.$804
- Johnson & Johnson$141
- Boston Scientific$125
- Myovant Sciences Inc.$121
- Bayer$25
- Bristol Myers Squibb$17
Across 15 payments — averaging $16,032 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$240K
- Merck$18
What the payments were for
- Travel & lodging$60149%
- Food & beverage$63251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elekta, Inc. | 4 | $804 |
| Johnson & Johnson | 1 | $141 |
| Boston Scientific | 1 | $125 |
| Myovant Sciences Inc. | 1 | $121 |
| Bayer | 2 | $25 |
| Bristol Myers Squibb | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,233 in reported general payments places this provider in the 70th percentile of 255 radiation oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 25 | $453 |
| Lidocaine Hcl ViscousLidocaine Hcl | 24 | $415 |
| Tamsulosin Hcl | 49 | $404 |
| Sucralfate | 14 | $251 |
| Oxycodone Hcl | 14 | $153 |
| Pantoprazole Sodium | 13 | $129 |
| Methylprednisolone | 15 | $110 |
| Omeprazole | 13 | $72 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Cincinnati
- Matthew BertkeCincinnati$5K
- John BrenemanCincinnati$5K
- Emily DaughertyCincinnati$2K
- Christopher FreeseCincinnati$2K
- Elizabeth LevickCincinnati$2K
- Steven KurtzmanGarfield Heights$833K
- Joshua PalmerColumbus$123K
- Norleena PoynterSandusky$90K
- Daniel SprattCleveland$86K
- Shlomo KoyfmanCleveland$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.